Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02664961 · ClinicalTrials.gov registry record · Phase 2
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
A Phase 2 study, sponsored by Tracon Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02664961 is a Phase 2 study that was terminated before completion, run by Tracon Pharmaceuticals. The registered enrollment target is 3 participants.
The verdict
NCT02664961, a Phase 2 study, was terminated before completion, sponsored by Tracon Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the overall response rate of single agent TRC105 and the combination of TRC105 and bevacizumab in patients with refractory GTN (including choriocarcinoma, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT)). Up to 30 patients will be treated.
Interventions
- DRUG Bevacizumab
- DRUG TRC105
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02664961
The ClinicalTrials.gov registry entry for NCT02664961 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tracon Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT02664961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02664961 about?
NCT02664961 is a clinical study titled "Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)". The purpose of the study is to determine the overall response rate of single agent TRC105 and the combination of TRC105 and bevacizumab in patients with refractory GTN (including choriocarcinoma, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT)). Up to 30 patients...
What is the current status of trial NCT02664961?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2016-03. Estimated completion is 2018-11.
What interventions are being tested in trial NCT02664961?
The interventions under investigation include: Bevacizumab (DRUG), TRC105 (DRUG).
Who is sponsoring clinical trial NCT02664961?
This trial is sponsored by Tracon Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.